Speaker: Joe Roemer, Sr. Director of Global Commercial IT Insight and Analytics, AstraZeneca

1. What science
can do
April 2020
Presented by:
Joseph Roemer

2. Graph Algorithms:
Proof of
concept
review
What’s
Next?
Today’s focus
April 20202
Who is
AstraZeneca?

3. Who is AstraZeneca?
1
3

4. AstraZeneca: global dimensions
For year ending 31 December 2019
April 20204
$24.4bn $6.1bn 70.6k
$23.6bn 167 45.4%
$819m 28 26
Total Revenue
(Up 10% in 2019)
invested in R&D
with research across
five countries
Product Sales
(Up 12% in 2019)
projects in clinical
development and
eight NMEs in late-
stage development
of our senior
roles are filled
by women
Collaboration
Revenue
NME approvals
in 2019
operations sites
in 16 countries
employees

5. Focus on three main therapy areas
and across key platforms
April 20205
BiologicsSmall molecules
Protein
Engineering
Devices
Oncology Respiratory
Cardiovascular, Renal
and Metabolism
Other Emerging
Drug Platforms
Combination of capabilities
Diagnostics

6. April 2020
Inspired by our values and what
science can do, we are focused on
accelerating the delivery of life-
changing medicines that create
enduring value for patients and
society.
We push the
boundaries of
science to deliver
life-changing
medicines
6

7. Graph Algorithms:
Proof of concept review
7
2

8. 8
Why we started exploring Graph?
Technology Scouting Research
April 2020

9. 9
Market Research -
Our entry point into the proof of concept
What other conditions
do these patients
typically have that are
being managed?
What other conditions
do these patients
typically have that are
being managed?
How do patients with
disease A get referred
to your practice?
How do patients with
disease A get referred
to your practice?
What is the patient
progression through the
disease, and how to you
help these patients?
What is the patient
progression through the
disease, and how to you
help these patients?
Traditional Patient Journey Research is delivered via phone interviews with a
cross section of Healthcare Professionals
What events cause you
to adjust treatment?
What events cause you
to adjust treatment?
April 2020

10. 10
Our proof of concept approach
Hypothesis
generation with
the Brand
Update the
graph model
Visualisation
April 2020

11. 11
Our proof of concept approach
Hypothesis
generation with
the Brand
Update the
graph model
Visualisation
April 2020

12. 12
Our proof of concept approach
Hypothesis
generation with
the Brand
Update the
graph model
Visualisation
April 2020

13. 13
Visualization helped Hypothesis Generation
Patient Journey – From start to finish
April 2020
Diagnosis Code Prescription Claim Procedure

14. 14
Question complexity lead us to Algorithms
Can we find all the patient
with similar but not exactly
the same journey?
How connected are
physicians in their treatment
of patients?
April 2020

15. 15
Patient Journey Similarity: Optimistic of the possibilities
April 2020

16. 16
Physician Connectedness & Influence

17. Insights from
our work with
graphs
17
Physicians work in tightly connected
groups with patient care spread
among the team
No two patient journeys are
the same but there are
similarities
Graph modeling requires a
change in mindset

18. What’s Next
18
3

19. 19
Graphs to highlight connections that matter
• Leverage graphs to better understand physician to health
system connectedness
• Finding influence points where physicians who have
experienced positive outcomes with patients connect to
other physicians who may still have questions

20. 20
Focus on insights from the patient journey
• More patient journey mapping to help focus our
conversations with health care providers on the
patients our medicines can help the most
• And if we do this well….. Hopefully build
predictive algorithms to help prevent avoidable
events like re-hospitalization

21. Thank You
21

22. Confidentiality Notice
This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove
it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this
file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203
749 5000, www.astrazeneca.com
22